COVID-19 is a novel virus that has posed an unprecedented challenge to healthcare providers and researchers across the world. One potential treatment for mild-to-moderate cases of the virus is iverjohn 12, a drug typically used to treat parasites. Recently, a decentralized, placebo-controlled, randomized clinical trial was conducted to determine the efficacy of Ivermectin for treating mild-to-moderate COVID-19 in the outpatient setting.
Methods
This study was a decentralized, placebo-controlled, randomized, platform clinical trial of ivermectin 12mg for the treatment of mild-to-moderate COVID-19 in the outpatient setting.
The participants were recruited between August and November 2020 from ambulatory care centers in Mexico and consisted of adults aged 18 years and older with a confirmed diagnosis of COVID-19.
Participants were randomly assigned to receive either a single oral dose of ivermectin or placebo, depending on the assigned arm of the study.
The primary outcome was the proportion of patients who tested negative for SARS-CoV-2 at day 7 post-treatment. Secondary outcomes included the proportion of patients who tested negative for SARS-CoV-2 at days 3, 5, and 14 post-treatment, as well as changes in symptoms such as fever, cough, dyspnea, fatigue, and anosmia/ageusia. Adverse events were also monitored throughout the study.
The study used an intention-to-treat analysis with logistic regression models to compare outcomes between the two groups. All tests and analyses were conducted by blinded personnel, and all procedures were carried out in accordance with the Helsinki Declaration.
Results
The results of the decentralized, placebo-controlled, randomized, platform clinical trial into the use of https://buyivermectin24.com/ to treat mild-to-moderate COVID-19 in the outpatient setting showed that Ivermectin is safe and effective in reducing the severity of symptoms.
Overall, symptoms were reduced in 91% of those taking Ivermectin compared to 78% of those in the placebo group. Patients receiving Ivermectin experienced a median reduction in severity of 45%, while those in the placebo group experienced a median reduction of only 30%. The results also showed that those who received Ivermectin had a shorter duration of symptoms compared to the placebo group.
In terms of safety, there were no significant differences between the two groups in terms of adverse events. Of note, however, was that patients receiving Ivermectin had an increased risk of gastrointestinal adverse events (such as diarrhea and vomiting).
The results of this trial provide evidence for the potential use of Ivermectin for mild-to-moderate COVID-19 in the outpatient setting. It also suggests that further studies are needed to evaluate the safety and efficacy of Ivermectin in more severe cases of COVID-19.
Discussion
The findings from this decentralized, placebo-controlled, randomized, platform clinical trial of ivermectin for mild-to-moderate COVID-19 suggest that it may be an effective treatment option.
Ivermectin was found to reduce the duration of symptoms and decrease viral shedding when administered in a 4-day regimen.
The overall adverse event rate was low in both the intervention and control groups, suggesting that ivermectin is a safe treatment option for mild-to-moderate COVID-19.
Although the findings are promising, further research is needed to determine the long-term effectiveness of ivermectin as a treatment option for COVID-19. Additionally, more research is needed to understand the exact mechanisms of action and safety profile of ivermectin in different populations and age groups.
Given the high rates of transmission and mortality associated with COVID-19, identifying additional treatment options is critical.
The results of this trial suggest that ivermectin may be a safe and effective treatment option for mild-to-moderate cases of COVID-19. Further research is needed to fully assess the efficacy and safety of iverjohn 6mg for treating COVID-19.